TF GUL

Docket No.:

DECLESS.1CP2DV

May 23, 2005 Page 1 of 1

Please Direct All Correspondence to Customer Number 20995

TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

Applicant

Moser, et al.

App. No

09/802,397

Filed

MAY 2 7 2005

March 9, 2001

For

DENDRITIC-LIKE CELL/TUMOR CELL

HYBRIDS AND HYBRIDOMAS FOR

INDUCING AN ANTI-TUMOR

RESPONSE

Examiner

Ewoldt, Gerald R.

Art Unit

1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 23, 2005

(Date)

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing and enclosing 2 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

Customer No. 20,995

Docket No.: DECLE55.1CP2DV

MAY 2 7 2005

INFORMATION DISCLOSURE STATEMENT

ANTI-TUMOR

plicant

Moser, et al.

App. No

09/802,397

Filed

March 9, 2001

For

DENDRITIC-LIKE CELL/TUMOR CELL

HYBRIDS AND HYBRIDOMAS FOR

INDUCING AN

Examiner

Ewoldt, Gerald R.

RESPONSE

Art Unit

1644

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 2 references to be considered by the Examiner. Also enclosed are 2 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R.§ 1.97(e)(2)

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 23, 2005

By:

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

1724253 052305

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAY 2 7 2005

Application No. 09/802,397

Filing Date March 9, 2001

First Named Inventor Moser, et al.

Art Unit 1644

Examiner Ewoldt, Gerald R.

Attorney Docket No. DECLE55.1CP2DV

(Multiple sheets used when necessary)
SHEET 1 OF 1

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear				

FOREIGN PATENT DOCUMENTS										
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹				

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹			
		Milicevic, et al. "Blood Lymphocytes, Monocytes and NK Cells Modulate Their Expression of CD44, ICAM-1, LFA-1 and MHC Class II After Arrival into Lymphoid Organs," <i>Immunol Invest.</i> , Vol. 33, No. 4, pp. 439-452, 2004, Abstract.				
 		Vremec, et al. "CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen," Journal of Immunology, Vol. 164, pp. 2978-2986, 2000.	,			

1724248 052305

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.